Top Markets
Coin of the day
SQZ Biotechnologies Company SQZ Biotechnologies Company

SQZ Biotechnologies Company

SQZ
Rang in Aktien #38920
SQZ Biotechnologies, a biotechnology firm currently in the clinical development... SQZ Biotechnologies, a biotechnology firm currently in the clinical development phase, is focused on creating cell-based therapies for various severe ailments, including cancerous growths, autoimmune disorders, and infectious diseases. Its primary experimental therapeutic, known as SQZ-PBMC-HPV, is derived from its SQZ Antigen Presenting Cells technology. This treatment is currently undergoing Phase I clinical trials, both as a standalone therapy and alongside other immune-oncology treatments, to address advanced or metastatic solid tumors positive for HPV16, encompassing cancers of the cervix, head-and-neck, anus, penis, vulva, and vagina. Furthermore, the company is progressing with SQZ-AAC-HPV, another Phase I clinical candidate targeting the same HPV16+ advanced or metastatic solid tumors, which is also being evaluated as a single agent and in conjunction with other immune-modulating agents. Beyond these, SQZ Biotechnologies is also advancing its SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers platforms. Established in 2013, the company operates from its main office in Watertown, Massachusetts.
Aktienkurs
$0.05083
Zuletzt synchronisiert: 2023-09-01
Marktkapitalisierung
$732.57K
Veränderung (1 Tag)
8.15%
Veränderung (1 Jahr)
0.00%
Land
US
Handel SQZ Biotechnologies Company (SQZ)

Kategorie

P/B-Verhältnis für SQZ Biotechnologies Company (SQZ)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von SQZ Biotechnologies Company beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für SQZ Biotechnologies Company von 2026 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
6.2613 -
US
6.3483 -
NL
- -
CH
- -
KR
3.634 -
BE